<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00166842</url>
  </required_header>
  <id_info>
    <org_study_id>910506</org_study_id>
    <secondary_id>NTUH S92</secondary_id>
    <nct_id>NCT00166842</nct_id>
  </id_info>
  <brief_title>Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets</brief_title>
  <official_title>Effects of Conversion From Sirolimus Oral Solution to Tablets in Renal Transplant Recipients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand the pharmacokinetics of sirolimus tablets in
      different regimens in newly renal transplant patients, and the effect of dosage form
      conversion on the concentration of sirolimus in stable renal transplant patients. So that we
      can design a better tacrolimus or cyclosporine/sirolimus/steroid dose regimen for Taiwanese.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sirolimus tablets will be available more than one year after the launch of sirolimus
      solution. Most patients on sirolimus solution will use sirolimus tablet instead.

      The purpose of this study is to understand the pharmacokinetics of sirolimus tablets in
      different regimens in newly renal transplant patients, and the effect of dosage form
      conversion on the concentration of sirolimus in stable renal transplant patients. So that we
      can design a better tacrolimus or cyclosporine/sirolimus/steroid dose regimen for Taiwanese.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2002</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of sirolimus tablets in different regimens in de novo renal transplant patients</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of dosage form conversion on sirolimus concentration in stable renal transplant patients.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of different sirolimus dose regimens in rejection prevention</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Transplantation</condition>
  <condition>Kidney Transplantation</condition>
  <condition>Immunosuppression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus, cyclosporine, tacrolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ages of 18 and 65, renal transplant patients

        Exclusion Criteria:

          -  pregnancy, tuberculosis, hepatitis B or C carrier status, human immunodeficiency
             virusÔºçpositive status, retransplantation or multiorgan transplantation, or history of
             rheumatoid arthritis before transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Po-Huang Lee, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Wu FL, Tsai MK, Sun SW, Chen RR, Huang JD, Lee PH. Effects of conversion from sirolimus oral solution to tablets in stable Taiwanese renal transplant recipients. J Formos Med Assoc. 2005 Jan;104(1):22-8.</citation>
    <PMID>15660173</PMID>
  </results_reference>
  <verification_date>July 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>September 12, 2005</last_update_submitted>
  <last_update_submitted_qc>September 12, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2005</last_update_posted>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Transplantation</keyword>
  <keyword>Kidney Transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

